Roche Holding AG

91% amyloid negativity at 28 weeks is impressive. ARIA-E only 1% vs 24% for donanemab - massive safety advantage. Brain Shuttle reaches deep brain regions. If clinical benefit matches biomarkers, could become preferred anti-amyloid. Peak $2-4B potential.

Roche failed twice before in Alzheimer's (gantenerumab). Amyloid clearance doesn't guarantee clinical benefit. One fatal bleed reported. Biogen/Lilly entrenched. Phase 3 risk remains high in AD.

Phase 2 data (22.5% weight loss) competitive with Wegovy/Zepbound. Signal-biased design may offer tolerability advantage. Massive TAM ($100B+). Manufacturing at scale is Roche strength. Zealand combo could differentiate. Genentech Holly Springs facility being built for metabolics.

Late to market vs Lilly/Novo who have years head start. Crowded pipeline (Amgen, Pfizer, Viking, etc.). No oral asset yet. Phase 3 will take years. May only capture small share of growing pie.

Parry: First oral SERD to win adjuvant. Convenience drives adoption. persevERA could open 1L mBC. evERA HR 0.56 shows differentiation.

Consensus: CDK4/6i dominant. Limited SERD differentiation. Adjuvant uptake slower than bulls think.

Orforglipron could be first successful oral GLP-1. Roche gets mid-single-digit tiered royalties. CHF2.4bn total over 10 years = CHF240M/year avg. Not in most models.

Oral GLP-1 efficacy may be lower than injectable. Competitive market. Royalty stream uncertain. Small contribution to CHF60bn+ company.

Parry: Giredestrant ($18bn), CT-388 ($8bn), fenebrutinib ($4.5bn), prasinezumab ($4.6bn), zilebesiran ($4.2bn), afimkibart ($3.8bn), NXT007 ($3bn), cevostamab ($2.4bn), pegozafermin ($2.7bn). Even 50% success = massive value creation.

Historic Ph3 success rates ~60%. Some targets (alpha-synuclein, TL1A) unvalidated. Consensus skeptical. Many "me-too" assets in crowded markets.

FcRH5 is novel target, no overlap with BCMA or GPRC5D. Post-BCMA patients need options. T-cell engager mechanism validated. Could be key sequencing option.

GPRC5D bispecifics (talquetamab) already in post-BCMA. Crowded myeloma market. CAR-T establishing dominance. Late entrant challenge.

Xolair up 32% in 2025 - food allergy stickier than expected. Biosimilar uptake may be slower given complex administration. Brand loyalty in allergies.

Multiple biosimilars launching H2 2026. Even if slower, 20-30% erosion over 2 years likely. CHF 3B product at risk.

Parry: 22.5% competitive. No plateau = higher ceiling. Oral could differentiate. Supply constraints create opening.

Late by 3-4 years. Lilly/Novo entrenched. Orforglipron may beat CT-388 oral.

Liver manageable (like teriflunomide). First BTKi in MS is huge. Brain-penetrant addresses smoldering inflammation.

REMS and monitoring needed. Neurologists prefer clean safety. May limit to PPMS niche.

Parry: First oral SERD to win adjuvant (lidERA). Convenience over tamoxifen drives rapid adoption. If persevERA wins, opens massive 1L mBC. evERA HR 0.56 suggests real differentiation.

Consensus: CDK4/6i combos already dominant in mBC. Limited room for SERD differentiation when CDK4/6i does heavy lifting. Adjuvant uptake slower than Parry assumes.

evERA showed HR 0.56 in post-CDK4/6i setting where tumors escaped. Oral SERD + CDK4/6i combo may achieve deeper ER suppression than AI + CDK4/6i. ESR1 mutations develop early.

monarchE showed CDK4/6i drives most benefit. AI vs SERD may be noise when CDK4/6i is backbone. persevERA may show minimal incremental benefit.

Enhertu for HER2-low is later-line. Giredestrant targets adjuvant/1L mBC where Enhertu not approved. Different positioning.

Enhertu highly efficacious. ADC mechanism may trump oral SERD. Giredestrant may be squeezed between CDK4/6i (1L) and ADCs (later).

Parry: 22.5% competitive with tirzepatide. No plateau suggests higher ceiling. Oral formulation could differentiate. Supply constraints at competitors create opening. Roche manufacturing scale.

Late to market by 3-4 years. Lilly/Novo entrenched with physicians. Oral GLP-1 (orforglipron) may beat CT-388 oral. Crowded market limits pricing power.

Liver signal manageable with monitoring (similar to teriflunomide). First BTKi in MS is huge achievement. Brain-penetrant MOA addresses smoldering inflammation. Worth the tradeoff.

Liver safety will require REMS and frequent monitoring. Neurologists prefer clean safety profiles. May limit to PPMS niche, missing larger RMS opportunity.

Brain Shuttle technology enables lower peripheral dosing. 91% plaque clearance with only 1% ARIA is transformational. Could enable broad treatment without MRI monitoring burden.

Phase 2 was small (n=100). ARIA rates could increase in larger, more diverse Phase 3 population. Prior AD drugs disappointed in pivotal trials.

Fast progressors had 35% delay in motor progression. PADOVA enriching for this population. Alpha-synuclein is the pathological hallmark - targeting it makes biological sense.

Many PD drugs have failed. PASADENA primary endpoint miss is concerning. Subgroup selection may not replicate. Alpha-synuclein may be passenger, not driver.

Growth drivers (Vabysmo +38%, Hemlibra +15%, Ocrevus SC) more than offset erosion. Xolair only ~6% of pharma revenue. Pipeline approvals add new growth.

Xolair contributed 32% of 2024 pharma growth. Erosion accelerates from H2 2026. Multiple biosim competitors = aggressive pricing. Legacy tails continue.

The major erosion already happened (2018-2022). Revenue from legacy biologics has stabilized at a floor. New products (Vabysmo, Hemlibra, Phesgo, Polivy) have more than offset.

Perjeta and Kadcyla biosimilars are coming next. Tecentriq faces PDL1 biosimilar competition. Actemra/RoActemra biosimilars are already eroding. Each legacy biologic that falls through the floor creates a new drag. The aggregate tail erosion is $1-2B/year — manageable but persistent. It means the pipeline needs to deliver just to stand still.

CT-388 (GLP-1/GIP dual agonist) showed 18.8% weight loss at 24 weeks in Phase 1 — extrapolated to potentially 25%+ at full duration. Roche brings global commercial infrastructure and payer relationships that smaller competitors lack. The obesity market ($150B+ TAM) is large enough for 5+ winners. $8B peak estimate is achievable even with 5% market share. CT-996 (next-gen oral) provides pipeline depth. Roche trades at 13x forward — any obesity success is almost free optionality.

LLY and NVO have 5+ year head start. Manufacturing at scale for GLP-1 peptides takes years. Phase 2/3 execution risk. The market may be saturated by the time CT-388 launches (2029+). The $8B peak assumes a competitive profile that has not been proven in Phase 3.